Skip to Main Content

China once had a reputation for punching below its weight when it came to biotech. These days, however, the country is a rapidly growing hotbed for biopharma investment and activity. The sector there is churning out news at a dizzying clip, generating excitement about a coming wave of new therapies — as well as concerns about whether China’s ecosystem is ready to handle it all.

To keep up with the latest about biotech in China, join a subscriber-only online chat with STAT reporter Rebecca Robbins, who has been closely covering the sector’s rise. Rebecca will address investment trends, drug pricing and reimbursement, Hong Kong’s quest to become a destination for biotech listings, and the most important data readouts and regulatory decisions to watch for this fall.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!